Evidence map›Paper›PMID 30356287›Full record

Trial reportPloS one2018

Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015.

Sikhulile Moyo, Simani Gaseitsiwe, Terence Mohammed, Molly Pretorius Holme, Rui Wang, Kenanao Peggy Kotokwe, Corretah Boleo, Lucy Mupfumi, Etienne Kadima Yankinda, Unoda Chakalisa and 17 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.Journal of acquired immune deficiency syndromes (1999) · 2019
    Article
  18. Article
  19. Article
  20. Lack of Virological Suppression Among Young HIV-Positive Adults in Botswana.Journal of acquired immune deficiency syndromes (1999) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.ORCID 0000-0003-3821-4592
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Terence MohammedBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Molly Pretorius HolmeBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Rui WangDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America.
Kenanao Peggy KotokweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Corretah BoleoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Lucy MupfumiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Etienne Kadima YankindaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Unoda ChakalisaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Erik van WidenfeltBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tendani GaolatheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Mompati O MmalaneBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Scott Dryden-PetersonBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Madisa MineBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Refeletswe LebelonyaneBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Kara BennettBennett Statistical Consulting, Inc., Ballston Lake, New York, United States of America.ORCID 0000-0002-9465-8983
Jean LeidnerGoodtables Data Consulting, Norman, OK, United States of America.
Kathleen E WirthDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Eric Tchetgen TchetgenDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston Massachusetts, United States of America.
Kathleen PowisBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Janet MooreU.S. Centers for Disease Control, Atlanta, Georgia, United States of America.
William A ClarkeJohns Hopkins Hospital, Baltimore, MD, United States of America.
Shahin LockmanBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Joseph M MakhemaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Max EssexBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Vlad NovitskyBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard University · USBotswana Harvard AIDS Institute Partnership · BWBrigham and Women's Hospital · USMinistry of Health · BWCenters for Disease Control and Prevention · USJohns Hopkins Hospital · US

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Methods to Advance the HIV Prevention Research AgendaR37AI051164 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI DEGRUTTOLA, VICTOR GERARD · 2012 to 2019
$3.3M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Risk factors for early morbidity and mortality of HIV-exposed uninfected infantsK23AI091434 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DRYDEN-PETERSON, SCOTT · 2012 to 2016
$659k
CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH001911FIC NIH HHS D43 TW010543NIAID NIH HHS K23 AI091434NIAID NIH HHS K24 AI131928NIAID NIH HHS R37 AI051164PEPFARWellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

backgroundBotswana is close to reaching the UNAIDS "90-90-90" HIV testing, antiretroviral treatment (ART), and viral suppression goals. We sought to determine HIV incidence in this setting with both high HIV prevalence and high ART coverage.

methodsWe used a cross-sectional approach to assessing HIV incidence. A random, population-based sample of adults age 16-64 years was enrolled in 30 rural and peri-urban communities as part of the Botswana Combination Prevention Project (BCPP), from October 2013 -November 2015. Data and samples from the baseline household survey were used to estimate cross-sectional HIV incidence, following an algorithm that combined Limiting-Antigen Avidity Assay (LAg-Avidity EIA), ART status (documented or by testing ARV drugs in plasma) and HIV-1 RNA load. The LAg-Avidity EIA cut-off normalized optical density (ODn) was set at 1.5. The HIV-1 RNA cut-off was set at 400 copies/mL. For estimation purposes, the Mean Duration of Recent Infection was 130 days and the False Recent Rate (FRR) was evaluated at values of either 0 or 0.39%.

resultsAmong 12,610 individuals participating in the baseline household survey, HIV status was available for 12,570 participants and 3,596 of them were HIV positive. LAg-Avidity EIA data was generated for 3,581 (99.6%) of HIV-positive participants. Of 326 participants with ODn ≤1.5, 278 individuals were receiving ART verified through documentation and were considered to represent longstanding HIV infections. Among the remaining 48 participants who reported no use of ART, 14 had an HIV-1 RNA load ≤400 copies/mL (including 3 participants with ARVs in plasma) and were excluded, as potential elite/viremic controllers or undisclosed ART. Thus, 34 LAg-Avidity-EIA-recent, ARV-naïve individuals with detectable HIV-1 RNA (>400 copies/mL) were classified as individuals with recent HIV infections. The annualized HIV incidence among 16-64 year old adults was estimated at 1.06% (95% CI 0.68-1.45%) with zero FRR, and at 0.64% (95% CI 0.24-1.04%) using a previously defined FRR of 0.39%. Within a subset of younger individuals 16-49 years old, the annualized HIV incidence was estimated at 1.29% (95% CI 0.82-1.77%) with zero FRR, and at 0.90% (95% CI 0.42-1.38%) with FRR set to 0.39%.

conclusionsUsing a cross-sectional estimate of HIV incidence from 2013-2015, we found that at the time of near achievement of the UNAIDS 90-90-90 targets, ~1% of adults (age 16-64 years) in Botswana's rural and peri-urban communities became HIV infected annually.

Indexed as

AdolescentAdultAnti-Retroviral AgentsBotswanaCross-Sectional StudiesFemaleHIV-1HIV AntibodiesHIV AntigensHIV InfectionsHumansIncidenceMaleMiddle AgedRural PopulationViral LoadAnti-Retroviral AgentsHIV AntibodiesHIV Antigens

Identifiers

PMID30356287
PMCPMC6200198
OpenAlexW2898274655

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.